HomeCompareCBDG vs ABBV

CBDG vs ABBV: Dividend Comparison 2026

CBDG yields 10989.01% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CBDG wins by $139745618573216752.00M in total portfolio value
10 years
CBDG
CBDG
● Live price
10989.01%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$139745618573216752.00M
Annual income
$137,288,015,193,820,900,000,000.00
Full CBDG calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — CBDG vs ABBV

📍 CBDG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBDGABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBDG + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBDG pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBDG
Annual income on $10K today (after 15% tax)
$934,065.93/yr
After 10yr DRIP, annual income (after tax)
$116,694,812,914,747,770,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, CBDG beats the other by $116,694,812,914,747,770,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBDG + ABBV for your $10,000?

CBDG: 50%ABBV: 50%
100% ABBV50/50100% CBDG
Portfolio after 10yr
$69872809286608376.00M
Annual income
$68,644,007,596,910,450,000,000.00/yr
Blended yield
98.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CBDG
No analyst data
Altman Z
-0.4
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBDG buys
0
ABBV buys
0
No recent congressional trades found for CBDG or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBDGABBV
Forward yield10989.01%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$139745618573216752.00M$104.7K
Annual income after 10y$137,288,015,193,820,900,000,000.00$25,725.73
Total dividends collected$139582332248243472.00M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CBDG vs ABBV ($10,000, DRIP)

YearCBDG PortfolioCBDG Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,109,601$1,098,901.10$11,559$438.51+$1.10MCBDG
2$115,144,457$113,957,183.82$13,494$640.86+$115.13MCBDG
3$11,175,031,832$11,051,827,262.66$15,951$945.97+$11175.02MCBDG
4$1,014,391,872,891$1,002,434,588,831.62$19,152$1,413.89+$1014391.85MCBDG
5$86,126,575,454,415$85,041,176,150,421.60$23,443$2,146.38+$86126575.43MCBDG
6$6,840,183,785,764,310$6,748,028,350,028,084.00$29,391$3,321.96+$6840183785.73MCBDG
7$508,187,488,422,178,800$500,868,491,771,411,000.00$37,948$5,265.87+$508187488422.14MCBDG
8$35,321,082,287,764,525,000$34,777,321,675,152,794,000.00$50,795$8,596.74+$35321082287764.48MCBDG
9$2,296,825,588,220,420,700,000$2,259,032,030,172,512,500,000.00$71,034$14,549.41+$2296825588220420.50MCBDG
10$139,745,618,573,216,750,000,000$137,288,015,193,820,900,000,000.00$104,715$25,725.73+$139745618573216752.00MCBDG

CBDG vs ABBV: Complete Analysis 2026

CBDGStock

THC Farmaceuticals, Inc. owns and operates non-financial institution cash-dispensing automated teller machines at third-party owned retail and commercial locations. The company's machines are placed in hotels, stores, bowling alleys, and other high customer traffic areas for small and medium sized businesses. As of June 30, 2015, it had a total of eight machines for public use along the Wasatch Front in the State of Utah. The company was formerly known as City Media, Inc. and changed its name to THC Farmaceuticals, Inc. in February 2015. THC Farmaceuticals, Inc. was founded in 2008 and is based in Scottsdale, Arizona. THC Farmaceuticals, Inc. operates as a subsidiary of Weed Growth Fund, Inc.

Full CBDG Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CBDG vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBDG vs SCHDCBDG vs JEPICBDG vs OCBDG vs KOCBDG vs MAINCBDG vs JNJCBDG vs MRKCBDG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.